Display options
Cite
Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;6:453-67doi: 10.2147/DMSO.S34416.
Rosenwasser, R. F., Sultan, S., Sutton, D., Choksi, R., & Epstein, B. J. (2013). SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy, 6453-67. https://doi.org/10.2147/DMSO.S34416
Rosenwasser, Rebecca F, et al. "SGLT-2 inhibitors and their potential in the treatment of diabetes." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 6 (2013): 453-67. doi: https://doi.org/10.2147/DMSO.S34416
Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. PMID: 24348059; PMCID: PMC3848644.
Copy Download .nbib Format: NLM
Share it on

Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416.

SGLT-2 inhibitors and their potential in the treatment of diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy

Rebecca F Rosenwasser, Senan Sultan, David Sutton, Rushab Choksi, Benjamin J Epstein

Affiliations

  1. East Coast Institute for Research, Jacksonville, FL, USA.
  2. Northeast Florida Endocrine and Diabetes Associates, Jacksonville, FL, USA.
  3. Department of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA.

PMID: 24348059 PMCID: PMC3848644 DOI: 10.2147/DMSO.S34416

Abstract

Diabetes remains a burgeoning global problem, necessitating ongoing efforts on the part of pharmaceutical and device manufacturers, patients, and society to curb the frightening trends in morbidity and mortality attributable to the malady. Since 1835 when phlorizin was discovered, sodium glucose co-transporter 2 (SGLT-2) inhibitors have rested tantalizingly on the horizon, promising a more physiological approach to glucose control. These agents lower glucose by enhancing its excretion by blocking reabsorption in the renal tubules, thus eliminating glucose from the body along with the molecules' attendant effects on caloric balance, plasma osmolality, and lipids. Consequently, SGLT-2 inhibitors improve glucose control to an extent comparable to other hypoglycemic agents while simultaneously reducing body weight, blood pressure, and cholesterol - an admirable portfolio. One agent, canagliflozin, has recently been approved by the US Food and Drug Administration (FDA) and two other agents have progressed through Phase III trials, including dapagliflozin and empagliflozin. Collectively, when used as monotherapy, these agents have demonstrated reductions in hemoglobin A1c (HbA1c), body weight, and blood pressure of -0.34% to -1.03%, -2.0 to -3.4 kg, and -1.7 to -6.4 mmHg/-0.3 to -2.6 mmHg (systolic blood pressure/diastolic blood pressure), respectively. SGLT-2 inhibitors have been well tolerated, with hypoglycemia (0.9% to 4.3%) occurring infrequently in clinical trials. Safety signals related to breast and bladder cancer have arisen with dapagliflozin, though these are unsubstantiated and likely ascribed to the presence of preexisting cancer. As these agents emerge, clinicians should embrace the addition to the formulary for treating type 2 diabetes, but must also weight the risk-benefit of this new class in deciding which patient types are most likely to benefit from their novel mechanism of action.

Keywords: canagliflozin; dapagliflozin; diabetes; empagliflozin; sodium–glucose transporter 2

References

  1. Diabetes Obes Metab. 2012 Oct;14(10):951-9 - PubMed
  2. Diabetes Care. 2010 Oct;33(10):2217-24 - PubMed
  3. Eur J Pediatr. 2013 Mar;172(3):409-11 - PubMed
  4. Eur J Endocrinol. 2012 Apr;166(4):711-6 - PubMed
  5. Rheum Dis Clin North Am. 2006 May;32(2):313-31, vi - PubMed
  6. Diabetes Care. 2009 Apr;32(4):650-7 - PubMed
  7. Diab Vasc Dis Res. 2012 Apr;9(2):117-23 - PubMed
  8. Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R75-83 - PubMed
  9. Lancet. 2012 Feb 11;379(9815):507 - PubMed
  10. Pflugers Arch. 2013 Jan;465(1):153-65 - PubMed
  11. Diabetes Educ. 2010 Jul-Aug;36 Suppl 3:44S-72S; quiz 73S-74S - PubMed
  12. Diabetes Obes Metab. 2009 Feb;11(2):79-88 - PubMed
  13. J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31 - PubMed
  14. Ann Intern Med. 2012 Mar 20;156(6):405-15 - PubMed
  15. Diabetes Care. 2011 Sep;34(9):2015-22 - PubMed
  16. Diabetes Obes Metab. 2011 Oct;13(10):928-38 - PubMed
  17. Pharmacol Ther. 2013 Jul;139(1):51-9 - PubMed
  18. Nat Rev Drug Discov. 2010 Jul;9(7):551-9 - PubMed
  19. Curr Diab Rep. 2012 Jun;12(3):230-8 - PubMed
  20. Diabetes Obes Metab. 2010 Jun;12(6):510-6 - PubMed
  21. Diabetes Care. 2012 Jul;35(7):1473-8 - PubMed
  22. Am J Kidney Dis. 2009 May;53(5):875-83 - PubMed
  23. Postgrad Med. 2011 Jul;123(4):38-45 - PubMed
  24. Heart. 2013 Jun;99(11):759-66 - PubMed
  25. Br J Clin Pharmacol. 2013 Sep;76(3):432-44 - PubMed
  26. Diabetes Care. 2013 Aug;36(8):2271-9 - PubMed
  27. Drug Saf. 2009;32(3):187-202 - PubMed

Publication Types